arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

MANGOCEUTICALS, INC.

MGRX

$0.49 0.00 (-0.37%) at close

5 Visible periods

23 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

MANGOCEUTICALS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $4.9M

Dividend Yield —

Revenue Growth -26.0% ↘

Op. Margin —

ROIC -93.7% ↘

FCF / Share $-0.58 ↗

Trailing P/E —

Price / Book 0.5x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

5-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$456.02K

↓ -26.0% —

Net Income Profit after all expenses

$-20.64M

↓ -137.1% —

FCF / Share Free cash flow per share

$-0.58

↑ +76.4% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Revenue Growth YoY (%)	-26.0% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-424%)	-15.8% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-298%)	8083.2% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+100940%)	—	—
EPS Growth YoY (%)	54.8% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	44.1% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-4415.8% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	-137.1% Weak ↑ Weak Improving Year-over-year change in net income	5.5% Fair Fair Year-over-year change in net income	-361.1% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	76.4% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	62.3% Excellent Excellent Year-over-year change in free cash flow	-4964.3% Weak Weak Year-over-year change in free cash flow	—	—
Revenue CAGR 3Y (%)	270.9% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
FCF / Net Income (x)	0.28x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.56x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.76x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.70x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Return on Invested Capital (%)	-93.7% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-45.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-940.0% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-256.2% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-112.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-51.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-877.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	-198.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-135.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1005%)	-62.4% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-516%)	—	—	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Interest Coverage (x)	—	—	-1424.21x Weak Weak Operating income divided by interest expense Optimal: > 5x	-307.68x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-1.49M	$-58.65K	$-739.01K	$-682.86K	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Revenue per Share (USD)	$0.05	$0.31	$0.68	$0.00	—
Basic EPS, GAAP (USD)	$-2.17	$-4.80	$-8.58	$-0.19	—
Free Cash Flow per Share (USD)	$-0.58	$-2.46	$-6.52	$-0.13	—
Book Value per Share (USD)	$0.96	$0.44	$0.54	$0.05	—
Tangible Book Value per Share (USD)	$0.06	$-0.04	$0.54	$0.05	—
Basic Weighted Avg Shares (shares)	10.07M	1.98M	1.07M	10.80M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Working Capital (USD)	$656.87K	$-1.35M	$624.32K	$434.03K	—
Total Equity (USD)	$15.20M	$13.95M	$774.75K	$614.03K	$-16.72K

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Sales/Revenue/Turnover (USD)	$456.02K	$615.87K	$731.49K	$8.94K	—
Depreciation Expense (USD)	$1.01K	$9.94K	$24.89K	$3.86K	—
Net Income, GAAP (USD)	$-20.64M	$-8.71M	$-9.21M	$-2.00M	—
Operating Cash Flow (USD)	$-5.85M	$-4.86M	$-7.00M	$-1.35M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 5 years · 18 quarters

MANGOCEUTICALS, INC.

Analytical Summary

5-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare MGRX with peers